

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT6584251

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
JINGRONG CAO	01/27/2021
JON H. COME	01/21/2021
LESLIE A. DAKIN	01/21/2021
FRANCOIS DENIS	01/21/2021
WARREN DORSCH	01/28/2021
ANNE FORTIER	01/20/2021
MARTINE HAMEL	01/21/2021
ELAINE KRUEGER	01/21/2021
BRIAN LEDFORD	01/20/2021
FRANCOIS MALTAIS	01/28/2021
SUGANTHINI NANTHAKUMAR	01/20/2021
OLIVIER NICOLAS	01/21/2021
CAMIL E. SAYEGH	01/23/2021
TIMOTHY J. SENTER	01/20/2021
TIANSHENG WANG	01/20/2021
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	VERTEX PHARMACEUTICALS INCORPORATED
<b>Street Address:</b>	50 NORTHERN AVENUE
<b>City:</b>	BOSTON
<b>State/Country:</b>	MASSACHUSETTS
<b>Postal Code:</b>	02210
<b>PROPERTY NUMBERS Total: 2</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	17161474
<b>PCT Number:</b>	US2021015495
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(202)408-4400
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	

PATENT

**Phone:** 2024084000  
**Email:** julie.giordano@finnegan.com  
**Correspondent Name:** FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER LLP  
**Address Line 1:** 901 NEW YORK AVENUE NW  
**Address Line 2:** ATTN: IP DEPARTMENT  
**Address Line 4:** WASHINGTON, D.C. 20001-4413

<b>ATTORNEY DOCKET NUMBER:</b>	10275.0168-00000
--------------------------------	------------------

<b>NAME OF SUBMITTER:</b>	SOFIA A. SANTOS
---------------------------	-----------------

<b>SIGNATURE:</b>	/Sofia A. Santos/
-------------------	-------------------

<b>DATE SIGNED:</b>	03/04/2021
---------------------	------------

**Total Attachments: 18**

source=10275.0168-Assignment#page1.tif  
source=10275.0168-Assignment#page2.tif  
source=10275.0168-Assignment#page3.tif  
source=10275.0168-Assignment#page4.tif  
source=10275.0168-Assignment#page5.tif  
source=10275.0168-Assignment#page6.tif  
source=10275.0168-Assignment#page7.tif  
source=10275.0168-Assignment#page8.tif  
source=10275.0168-Assignment#page9.tif  
source=10275.0168-Assignment#page10.tif  
source=10275.0168-Assignment#page11.tif  
source=10275.0168-Assignment#page12.tif  
source=10275.0168-Assignment#page13.tif  
source=10275.0168-Assignment#page14.tif  
source=10275.0168-Assignment#page15.tif  
source=10275.0168-Assignment#page16.tif  
source=10275.0168-Assignment#page17.tif  
source=10275.0168-Assignment#page18.tif

## ASSIGNMENT

WHEREAS We, the below-named inventor(s) (hereinafter referred to as Assignor(s)), of an invention entitled:

### INHIBITORS OF APOL1 AND METHODS OF USING SAME

claiming priority to United States Provisional Patent Application No. 62/967,276 filed January 29, 2020, United States Provisional Patent Application No. 63/038,278 filed June 12, 2020, and United States Provisional Patent Application No. 63/040,166 filed June 17, 2020, and as disclosed and claimed in the applications identified below this paragraph, and:

Application Number*	Country of Filing	Filing Date
PCT/US2021/015495	PCT	January 28, 2021
17/161,474	US	January 28, 2021

\* We authorize and request a patent practitioner of record in this application to insert the application number of the above referenced applications when known.

by virtue of our agreements with Vertex Pharmaceuticals Incorporated, a corporation of Massachusetts whose post office address is 50 Northern Avenue, Boston, Massachusetts 02210, USA (hereinafter referred to as Assignee), confirm assignment and hereby assign to assignee the entire right, title, and interest in and to this invention in all countries throughout the world, and in and to all applications for patents on this invention in all countries throughout the world, including any PCT International Application and all national stage applications based thereon that may be filed, and all patents issued upon such applications in all countries throughout the world;


NOW THEREFORE, be it known that, for good and valuable consideration the receipt of which from Assignee is hereby acknowledged, We, as Assignors, confirm that all rights in the inventions and applications listed above automatically transferred to Assignee by virtue of our agreements. For the avoidance of doubt, Assignors hereby confirm having sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto the Assignee, its lawful successors and assigns, my/our entire right, title, and interest in and to this invention, the above-referenced applications that disclose and/or claim this invention, any PCT International Application and all national stage applications based thereon that may be filed, any other applications for patents filed anywhere in the world that claim this invention, and all divisions, and continuations of any such application, and all patents which may be granted thereon, and all reissues thereof, and all rights to claim priority in any country on the basis of any such applications, and all extensions, renewals, and reissues thereof; and We hereby authorize and request that any official of any country whose duty it is to issue patents on applications as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, WE covenant that have not executed and will not execute any agreement in conflict with this Assignment;


AND, WE further covenant and agree that We will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to us respecting this invention, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that may be necessary or desirable to perfect the title to this invention in said Assignee, its successors or assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for this invention in the United States and any foreign country, it being understood that any expense incident to the execution of such papers shall be borne by the Assignee, its successors and assigns.

IN TESTIMONY WHEREOF, We have hereunto set our hands.

JOINT INVENTION  
(Worldwide Rights)  
Attorney Docket Nos.: VPI 19-127  
10275.0168

  
Jingrong CAO

Date: 1-27-2021

  
\_\_\_\_\_  
Jon H. COME

Date: Jan 21, 2021


\_\_\_\_/Leslie A Dakin/\_\_\_\_\_  
Leslie A. DAKIN

Date: \_\_\_\_ 1/21/2021 \_\_\_\_\_

*Francois Denis*  
Francois DENIS

Date: *January 21, 2021*






Warren DORSCH

Date: 1/28/2021

\_\_\_\_\_/Anne Fortier/\_\_\_\_\_  
Anne FORTIER

Date: \_\_\_\_\_January 20th 2021\_\_\_\_\_

Martine Hamel  
Martine HAMEL  
Date: 21/01/2021

  
Elaine KRUEGER

Date: January 21, 2021

JOINT INVENTION  
(Worldwide Rights)  
Attorney Docket Nos.: VPI 19-127  
10275.0168



Brian LEDFORD

Date: 1-20-21

/François Maltais/


Francois MALTAIS

Date: 01/28/2021

JOINT INVENTION  
(Worldwide Rights)  
Attorney Docket Nos.: VPI 19-127  
10275.0168

Suganthini Nanthakumar  
Suganthini NANTHAKUMAR

Date: 01/20/2021



Olivier NICOLAS

Date:

JANUARY 21<sup>st</sup> 2021



/Camil E. Sayegh/

Camil E. SAYEGH

Date: January 23, 2021

*/Timothy Senter/*

---


Timothy J. SENTER

Date: January 20th, 2021

/Tiansheng Wang/  
Tiansheng WANG

Date: 01/20/2021

ACKNOWLEDGEMENT OF ASSIGNEE



Name: Konstantinos Andrikopoulos  
Title: Executive Director, IP  
On behalf of Vertex Pharmaceuticals Incorporated

Date January 28, 2021